In line with this, Nayar and colleagues described the appearance of HER2 mutations in metastatic lesions from eight ER+ BC patients under the selective pressure of ER-directed aromatase inhibitors, tamoxifen, or fulvestrant. This evidence concerns the gene ERBB2 and breast cancer.